Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The computation of Net Loss per Common Share Basic and Diluted, is based on the weighted-average number of shares outstanding of Common Stock. In computing diluted loss per share, no effect has been given to the shares of common stock issuable upon the conversion or exercise of the following dilutive securities, as the Company’s net loss would make the effect anti-dilutive.

	March 31, 2018 (unaudited)		March 31, 2017 (unaudited)
Common Stock Warrants		9,455,961		2,852,736
Employee Stock Options		2,167,003		1,489,934
Total Shares of Common Stock Issuable		11,622,964		4,342,670

Schedule Of Cummulative effect Of Revenue Recognition To Condensed Balance Sheet

The cumulative effect of initially applying the new revenue recognition guidance to the Company’s Condensed Consolidated Balance Sheet on January 1, 2018 was as follows:

			Cumulative Impact
	Balance as of		from Adopting New		Balance as of
	December 31, 2017		Revenue Guidance		January 1, 2018
Assets:
Unbilled Revenue		-		116,280		116,280

Liabilities:
Deferred Revenue		12,313,600		(9,361,600)		2,952,000

Stockholders' Equity:
Accumulated Deficit		(91,816,655)		9,477,880		(82,338,775)

Schedule Of Impact From Adopting The New Revenue Recognition Guidance On The Condensed Financial Statements

The impact from adopting the new revenue recognition guidance on the Company’s Condensed Consolidated Financial Statements was as follows:

			Previous		Impact from
		As Reported	Accounting		Adopting New
	March 31, 2018		Guidance		Revenue Guidance
Condensed Consolidated Balance Sheet
Assets:
Unbilled Revenue		922,488		-		922,488

Liabilities:
Deferred Revenue		2,860,000		12,511,400		(9,651,400)

Stockholders' Equity:
Accumulated Deficit		(84,718,102)		(95,291,990)		10,573,888

Condensed Consolidated Statement of Operations and Comprehensive Loss

Collaboration Revenue		1,096,008		-		1,096,008

Operating Loss Before Other Expenses		(2,379,049)		(3,475,057)		1,096,008

Net Loss		(2,379,327)		(3,475,335)		1,096,008

Comprehensive Loss		(2,378,093)		(3,474,101)		1,096,008

Contract with Customer, Asset and Liability

The below table represents the changes in the Company’s contract assets and contract liabilities:

	March 31, 2018		January 1, 2018
Contract Asset:
Unbilled Revenue		922,488		116,280

Contract Liabilities:
Deferred Revenue		2,860,000		2,952,000

	Three Months Ended
	March 31, 2018
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period		92,000